Pneumopathie interstitielle induite par la mésalazine

Lamsiah, Taoufik; Moudden, K.; Baaj, M. El; Hadri, L.

doi:10.1016/j.gcb.2009.08.013

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also considered that mesalazine was a likely cause of his acute illness as lung damage is rarely seen soon after the drug has been administered [ 12 – 15 ], and TBLB showed nonspecific interstitial inflammation without any findings of vasculitis. In our case, the dyspnea began 3 months after the mesalazine had been started, and the finding of predominantly CD8-positive cells in the BAL was suggestive of drug-induced lung injury.…”

Section: Discussionmentioning

confidence: 99%

Recurrent Interstitial Pneumonitis in a Patient with Entero-Behçet’s Disease Initially Treated with Mesalazine

Nakamura

Miyamura

et al. 2016

Case Reports in Rheumatology

View full text Add to dashboard Cite

A 65-year-old man with entero-Behçet's disease (BD) being treated with mesalazine was presented to our hospital complaining of dyspnea. Computed tomography (CT) of the chest showed ground-glass opacities and he was initially diagnosed with mesalazine-induced interstitial pneumonitis (IP). Besides the discontinuation of mesalazine, a high dose of oral prednisolone was administered and the patient seemed to recover. However, four months later, dyspnea recurred and repeated CT revealed more extensive pulmonary infiltration despite steroid therapy. After the exclusion of infections, we suspected either a recurrence of mesalazine-induced IP or BD-related IP as a clinical manifestation of BD. The patient was treated with intravenous methylprednisolone and cyclophosphamide, followed by orally administered azathioprine, based on the assumption of underlying vasculitis. Thereafter, his condition improved. BD-related IP is an extremely rare condition with limited reports in the literature. Mesalazine-induced IP is also uncommon but the prognosis is generally good after discontinuation of mesalazine with or without steroid therapy. We discuss an extremely rare case, especially focusing on BD-related IP and mesalazine-induced IP as a potential cause of recurrent IP in a patient with entero-BD.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent Interstitial Pneumonitis in a Patient with Entero-Behçet’s Disease Initially Treated with Mesalazine

Nakamura

Miyamura

et al. 2016

Case Reports in Rheumatology

View full text Add to dashboard Cite

show abstract

“…Częstość występowania manifestacji płucnych w przebiegu NChZJ wynosi od 20 do nawet 40% [7,12,14]. Rzadziej dochodzi do powikłań płucnych po stosowanej farmakoterapii, najczęściej o charakterze infekcyjnym, ale także z powodu nadwrażliwości na stosowane leki.…”

Section: Dyskusjaunclassified

Pulmonary Manifestations of Crohn’s Disease or Chronic Pharmacotherapy Complications? – Case Report

Rakoczy

Liczek²,

Panek³

et al. 2020

Wiad Lek

View full text Add to dashboard Cite

Pareneteral manifestations of Crohn’s disease (ChLC), apart from the most common skin and joint symptoms include also complications from the respiratory system. In addition chronic pharmacotherapy of ChLC, especially 5-aminosalicylic acid or anti-TNF- α drugs, is associated with possible pulmonologic side effects, sometimes difficult to differentiate. In this study, we describe a patient with ChLC, with a history of pneumocystic pneumonia, who was diagnosed with exfoliative institial pneumonitis as a result of chronic use of mesalazine. This disease is characterized by accumulation of alveolar macrophages in the lumen of the alveoli and intrabepticular septum. The most common etiologic factor is exposure to tobacco smoke. Our patient, non-smoker, was finally diagnosed after lung biopsy and histopathological evaluation. The gradual clinical improvement after mesalazine was an additional factor confirming the etiology of the disease. This side effect of mesalazine is not common but it should be considered in all patient treated with 5-aminosalicylic acid.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Pneumopathie interstitielle induite par la mésalazine

Cited by 6 publications

References 11 publications

Recurrent Interstitial Pneumonitis in a Patient with Entero-Behçet’s Disease Initially Treated with Mesalazine

Recurrent Interstitial Pneumonitis in a Patient with Entero-Behçet’s Disease Initially Treated with Mesalazine

Pulmonary Manifestations of Crohn’s Disease or Chronic Pharmacotherapy Complications? – Case Report

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About